Compare Novo Nordisk A/S (NVO) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Consumer Staples Select Sector SPDR Fund — how do they compare? Novo Nordisk A/S trades at $44.72 (market cap $200.69B), while Consumer Staples Select Sector SPDR Fund trades at $83.1. The key difference: Novo Nordisk A/S pays a 3.98% dividend while Consumer Staples Select Sector SPDR Fund pays none, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | XLP | |
|---|---|---|
Market Cap | $200.69B | — |
Sector | Health | — |
52-Week High | $63.98 | $90.00 |
52-Week Low | $35.29 | $75.61 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $84.02, down 0.66% on the day amid broader market volatility. The technical picture shows bearish momentum with selling pressure outweighing buying signals 14 to 6, though oscillators suggest potential stabilization. Analyst consensus remains strongly positive with 100% buy ratings, highlighting XLP's defensive characteristics during economic uncertainty. Recent news emphasizes the fund's appeal as a safe haven with its 2.6% dividend yield and exposure to stable consumer staples companies.
XLP offers defensive exposure to essential consumer goods companies, providing stability during market turbulence. The fund's low 0.08% expense ratio and consistent dividend payments support its appeal for risk-averse investors. However, limited growth potential compared to cyclical sectors and sensitivity to consumer spending trends present ongoing challenges for significant price appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
